NRC-AN-019
CAS: 879507-25-2
Ref. 3D-EKB50725
| 1mg | A consultar | ||
| 5mg | A consultar | ||
| 10mg | A consultar | ||
| 25mg | A consultar | ||
| 50mg | A consultar |
Información del producto
NRC-AN-019 is an imatinib-resistant drug that belongs to the class of bcr-abl inhibitors. It has been shown to be effective in women with metastatic breast cancer and who are resistant to lapatinib and imatinib. NRC-AN-019 is a polymeric matrix that contains epidermal growth factor (EGF) and is designed for topical administration. The drug binds to the receptor tyrosine kinase erbB2, which prevents it from binding with the epidermal growth factor receptor (EGFR). This leads to suppression of cellular proliferation, differentiation, and angiogenesis. NRC-AN-019 also has pharmacokinetic properties that allow for escalation of dosage without significant toxicities or side effects.
Propiedades químicas
Consulta técnica sobre: 3D-EKB50725 NRC-AN-019
Si desea solicitar un presupuesto o realizar un pedido, por favor añada los productos deseados a su carrito y solicite un presupuesto o pedido desde el carrito. Es más rápido, más barato, y podrá beneficiarse de los descuentos y las ventajas disponibles.
